Ascelia Pharma: Secures full support from the completed Rights Issue

Research Note

2024-09-04

11:20

The preliminary result is 100% support and a gross proceed of SEK 105m. This outcome also adds future support from warrants due in spring 2025, adding up to SEK 30m gross (based on today’s share price). Ascelia Pharma (Ascelia) expects to confirm the outcome on 5 September. The preliminary result is distinctly positive for Ascelia as it reduces the financial uncertainty and allows Ascelia to proceed with Orviglance’s FDA submission process and advance discussion with future commercial partners ahead of the launch.

Johan Unnerus

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.